NRC Issues Construction Permit to Northwest Medical Isotopes LLC

On May 9, 2017, NRC announced that agency staff has issued a construction permit to Northwest Medical Isotopes LLC (NWMI) for a molybdenum-99 production facility in Columbia, Missouri.  The permit is for a site at the Discovery Ridge Research Park.


The Commissioners authorized the Director of the NRC’s Office of Nuclear Reactor Regulation to issue the permit following a hearing on the application on January 23, 2018.  The Commission found the staff’s review of the application sufficient to make the necessary regulatory safety and environmental findings.

NWMI submitted its application for permission to build the facility in two parts on February 5, 2015 and July 20, 2015.  It will produce molybdenum-99, which later generates the technicium-99m that is used in one of the most common nuclear medicine procedures in the United States.


The NRC’s Advisory Committee on Reactor Safeguards (ACRS) independently reviewed aspects of the application that concerned safety, as well as the staff’s safety evaluation report.  The committee provided the results of its review to the Commission in November 2017.

The staff completed its environmental review and issued the final environmental impact statement for the proposed facility in May 2017.

For additional information, please contact Scott Burnell of the NRC at (301) 415-8200.

Comments Sought re Proposed Medical Radioisotope Production Facility

On November 15, 2016, the U.S. Nuclear Regulatory Commission (NRC) announced that the agency is seeking public comment on its Draft Environmental Impact Study of a medical radioisotope production facility proposed for Columbia, Missouri.

The study recommends a construction permit be issued to Northwest Medical Isotopes LLC, barring any safety issues identified in the agency’s ongoing technical review of the application.


The DEIS (NUREG-2209) documents the NRC staff’s environmental review of Northwest’s construction authorization application.  It examines the environmental impacts of construction, operation and decommissioning of the proposed facility, as well as the transportation and irradiation of uranium targets at research reactors.  It concludes the environmental impacts would be small and therefore not be significant enough to deny the construction permit.

On December 6, 2016, NRC staff held a public meeting in Columbia to present the draft study’s findings and receive public comment.  Agency staff members were on hand one hour before the meeting for informal discussions with members of the public.


NRC accepted comments on the DEIS at the public meeting on December 6, 2016.  Comments may also be submitted in writing online at using Docket ID NRC-2013-0235.  Comments will be accepted through December 29, 2016.  Additional information on the public meeting and how to submit comments was published in the Federal Register on November 9, 2016.


In February 2015, Northwest submitted an application proposing to construct a facility to produce molybdenum-99 from low-enriched uranium.  Molybdenum-99 decays to technetium-99m, the most commonly used radioisotope in medicine.  Technetium-99m is used in 20 million to 25 million diagnostic procedures around the world each year, such as bone and organ scans to detect cancer, and cardiovascular imaging.  There are currently no molybdenum-99 production facilities in the United States, though the NRC has issued a construction authorization to SHINE Medical Technologies to build one in Janesville, Wisconsin.

For additional information, please contact David McIntyre of the NRC at (301) 415-8200.